JP2020515533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515533A5 JP2020515533A5 JP2019550683A JP2019550683A JP2020515533A5 JP 2020515533 A5 JP2020515533 A5 JP 2020515533A5 JP 2019550683 A JP2019550683 A JP 2019550683A JP 2019550683 A JP2019550683 A JP 2019550683A JP 2020515533 A5 JP2020515533 A5 JP 2020515533A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- meibomian
- agent
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 15
- 210000004175 Meibomian Glands Anatomy 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims 2
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003410 keratolytic agent Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 229960000458 Allantoin Drugs 0.000 claims 1
- 239000004342 Benzoyl peroxide Substances 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 229940108066 Coal Tar Drugs 0.000 claims 1
- 210000000744 Eyelids Anatomy 0.000 claims 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims 1
- 229960000448 Lactic acid Drugs 0.000 claims 1
- 239000004166 Lanolin Substances 0.000 claims 1
- 229940039717 Lanolin Drugs 0.000 claims 1
- 229940114937 MICROCRYSTALLINE WAX Drugs 0.000 claims 1
- 229940042472 Mineral Oil Drugs 0.000 claims 1
- 229940056211 Paraffin Drugs 0.000 claims 1
- 239000004264 Petrolatum Substances 0.000 claims 1
- 229940066842 Petrolatum Drugs 0.000 claims 1
- 229940046307 SODIUM THIOGLYCOLATE Drugs 0.000 claims 1
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N Selsun Blue Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 claims 1
- 229940031439 Squalene Drugs 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- 229940045136 Urea Drugs 0.000 claims 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 1
- 235000019400 benzoyl peroxide Nutrition 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 229960002645 boric acid Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229960000539 carbamide Drugs 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- -1 disanol Chemical compound 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 235000019388 lanolin Nutrition 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000004132 lipogenesis Effects 0.000 claims 1
- 239000004200 microcrystalline wax Substances 0.000 claims 1
- 235000019808 microcrystalline wax Nutrition 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229910000338 selenium disulfide Inorganic materials 0.000 claims 1
- 229960005265 selenium sulfide Drugs 0.000 claims 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
Claims (11)
- 前記眼科的に許容可能な担体は、少なくとも1つの眼科的に許容可能な賦形剤を含む、請求項1に記載の組成物。
- 前記方法は、前記患者に角質溶解剤を投与する工程をさらに含む、請求項1に記載の組成物。
- 前記角質溶解剤は、過酸化ベンゾイル、コールタール、ジスラノール、サリチル酸、二硫化セレン、アルファヒドロキシ酸、尿素、ホウ酸、レチノイン酸、乳酸、チオグリコール酸ナトリウム、またはアラントイン、からなる群から選択される、請求項3に記載の組成物。
- 前記薬剤を約0.01%から約10%の間で含む、請求項1に記載の組成物。
- 前記薬剤を約2.5%含む、請求項5に記載の組成物。
- 前記薬剤を約0.1μMから約1μMの間で含む、請求項1に記載の組成物。
- 分散液、懸濁液、またはエマルジョンである、請求項1に記載の組成物。
- パラフィン、ワセリン、スクワレン、マイクロクリスタリンワックス、ラノリン、鉱油、植物油、トリグリセリド、リン脂質、またはそれらの組み合わせを含む、請求項1に記載の組成物。
- 前記患者は、マイボーム腺機能不全を患っている、請求項1に記載の組成物。
- 前記マイボーム腺機能不全は、マイボーム腺の閉塞を特徴とする、請求項10に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762478501P | 2017-03-29 | 2017-03-29 | |
US62/478,501 | 2017-03-29 | ||
PCT/IB2018/000415 WO2018178769A1 (en) | 2017-03-29 | 2018-03-28 | Agents for increasing meibomian gland lipid secretion |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020515533A JP2020515533A (ja) | 2020-05-28 |
JP2020515533A5 true JP2020515533A5 (ja) | 2021-05-06 |
JP7105244B2 JP7105244B2 (ja) | 2022-07-22 |
Family
ID=63674495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019550683A Active JP7105244B2 (ja) | 2017-03-29 | 2018-03-28 | マイボーム腺脂質分泌を増加させるための薬剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11484516B2 (ja) |
EP (1) | EP3600272A4 (ja) |
JP (1) | JP7105244B2 (ja) |
KR (1) | KR102541236B1 (ja) |
CN (1) | CN110719775A (ja) |
AU (1) | AU2018247122A1 (ja) |
BR (1) | BR112019020444A2 (ja) |
CA (1) | CA3057569A1 (ja) |
MX (1) | MX2019011697A (ja) |
WO (1) | WO2018178769A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102541236B1 (ko) | 2017-03-29 | 2023-06-08 | 아주라 오프탈믹스 엘티디 | 마이봄샘 지질 분비 증가를 위한 작용제 |
CA3136369A1 (en) | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
JP2022530322A (ja) | 2019-04-18 | 2022-06-29 | アズーラ オフサルミックス エルティーディー. | 眼障害を処置するための化合物および方法 |
EP4087655A4 (en) | 2020-01-10 | 2024-02-21 | Azura Ophthalmics Ltd | INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY |
US20210308154A1 (en) | 2020-03-24 | 2021-10-07 | Hovione Scientia Limited | Methods and Compositions for Treating Meibomian Gland Dysfunction |
US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1258781B (it) | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
JP3496114B2 (ja) | 1997-08-29 | 2004-02-09 | 参天製薬株式会社 | 角膜新生血管増殖抑制剤 |
US20070166402A1 (en) * | 2005-12-12 | 2007-07-19 | Friedlaender Mitchell H | Compositions, methods and kits for removing debris from an ocular area |
GB0604822D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders and pain |
JP4987078B2 (ja) | 2006-11-30 | 2012-07-25 | 株式会社メニコン | 眼科用組成物 |
LT2493474T (lt) * | 2009-10-30 | 2019-10-10 | Intratus, Inc. | Būdai ir kompozicijos prolonguotam vaistų įvedimui |
US20110218241A1 (en) * | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
US20140142055A1 (en) * | 2011-06-29 | 2014-05-22 | Insite Vision Corporation | Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence |
AU2013299785B2 (en) * | 2012-08-06 | 2017-09-07 | Baylor College Of Medicine | Therapeutics dispensing device and methods of making same |
US9610385B2 (en) | 2013-03-07 | 2017-04-04 | Abbott Cardiovascular Systems Inc. | Method of fabricating an implantable medical device comprising a rapamycin derivative |
PT3139903T (pt) * | 2014-05-07 | 2019-10-24 | Croma Pharma Ges M B H | Solução oftálmica aquosa e método para tratar a síndrome do olho seco. |
US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
US10688122B2 (en) * | 2015-09-28 | 2020-06-23 | Azura Ophthalmics Ltd. | Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion |
KR102541236B1 (ko) | 2017-03-29 | 2023-06-08 | 아주라 오프탈믹스 엘티디 | 마이봄샘 지질 분비 증가를 위한 작용제 |
-
2018
- 2018-03-28 KR KR1020197032100A patent/KR102541236B1/ko active IP Right Grant
- 2018-03-28 WO PCT/IB2018/000415 patent/WO2018178769A1/en unknown
- 2018-03-28 AU AU2018247122A patent/AU2018247122A1/en not_active Abandoned
- 2018-03-28 EP EP18776954.2A patent/EP3600272A4/en active Pending
- 2018-03-28 CA CA3057569A patent/CA3057569A1/en active Pending
- 2018-03-28 MX MX2019011697A patent/MX2019011697A/es unknown
- 2018-03-28 BR BR112019020444A patent/BR112019020444A2/pt not_active Application Discontinuation
- 2018-03-28 US US16/498,299 patent/US11484516B2/en active Active
- 2018-03-28 CN CN201880036171.6A patent/CN110719775A/zh active Pending
- 2018-03-28 JP JP2019550683A patent/JP7105244B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020515533A5 (ja) | ||
JP2019534867A5 (ja) | ||
JP2018533622A5 (ja) | ||
EP0280797B1 (en) | Medicaments for treatment of ocular inflammation | |
CA2424444A1 (en) | Topical antibiotic composition for treatment of eye infection | |
CN103948603A (zh) | 用于治疗粘膜疾病的方法和组合物 | |
KR960700039A (ko) | β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor) | |
JP4314433B2 (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
JP5542059B2 (ja) | Rxr作動性物質を有効成分とする抗アレルギー剤 | |
DE60008151T2 (de) | 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom | |
JP2005529851A5 (ja) | ||
JP2010184903A (ja) | 外用医薬組成物 | |
JP2018510855A5 (ja) | ||
JP2005505592A (ja) | 抗炎症性ステロイドとmuc−1分泌促進薬との組み合わせによる、ドライアイを処置するための方法 | |
ES2379652T3 (es) | Compuestos de prostaglandina para el tratamiento de obesidad | |
US8889735B2 (en) | Method for treating asthenopia | |
RU2548762C2 (ru) | Способ и композиция для лечения дегенерации желтого пятна | |
Guex-Crosier | Non-steroidal anti-inflammatory drugs and ocular inflammation | |
JP2009227672A (ja) | 皮膚に対する鎮痛効果を提供するための組成物 | |
AU664042B2 (en) | Method and composition for treatment of gastric and duodenal disorders and new PGE2-derivatives | |
ES2358558T3 (es) | Derivados de tiofeno como medicamentos para el tratamiento de la hipertensión ocular. | |
CN100506232C (zh) | 用于治疗眼压过高和青光眼的组合物 | |
ES2717481T3 (es) | Engrosamiento corneal central reducido mediante el uso de profármacos de ésteres hidrófilos de beta-clorociclopentanos | |
JP2003292442A (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
JP5011548B2 (ja) | 高眼圧症あるいは緑内障の処置用医薬組成物 |